HIV Envelope Protein Trimer Stabilization via SOSIP Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine development faces challenges in producing stable envelope proteins that induce broadly neutralizing antibodies, due to high genetic variability, dynamic protein structure, and low trimer formation efficiency, limiting the breadth of neutralizing antibody responses.
Innovation Solution
Recombinant HIV envelope proteins with specific amino acid mutations at positions 658, 651, 655, 535, 589, 573, and 647 are optimized to improve trimer formation and stability, enhancing the induction of broadly neutralizing antibodies while reducing non-neutralizing antibody responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If stabilizing modifications are introduced into the envelope structure, then the stability of the envelope protein is improved, but the immunogenicity is reduced due to shielding of protein epitopes by dense carbohydrate coat
Solution Approach 1:
The patent modifies the envelope protein structure by introducing specific stabilizing mutations (such as SOSIP mutations: 501C, 605C, 559P) that change the physical-chemical parameters of the protein. These mutations stabilize the prefusion conformation while maintaining antigenic determinants accessible to antibodies, thus resolving the contradiction between stability and immunogenicity
Solution Approach 2:
The patent applies local modifications at specific positions (501, 605, 559) of the envelope protein rather than global changes. This allows stabilization of the overall structure while preserving local epitopic regions that are critical for immune recognition, thereby maintaining immunogenicity while improving stability
2Stability of the object's composition
If focus is placed on producing soluble gp140 trimer fraction, then the trimer stability is improved, but the percentage of trimer formation remains below 10% with large amounts of monomer and aggregates
Solution Approach 1:
The patent introduces specific amino acid substitutions (cysteine at positions 501 and 605, proline at position 559) that fundamentally change the structural parameters of the envelope protein. These changes enable disulfide bridge formation and proper folding, increasing trimer formation from below 10% to significantly higher levels while reducing monomer and aggregate production
Solution Approach 2:
The patent creates a composite structural arrangement within the envelope protein by forming disulfide bonds between cysteine residues at specific positions. This composite covalent linkage stabilizes the trimeric structure and promotes efficient trimer formation, converting a structurally labile protein into a stable immunogen
3Stability of the object's composition
If the envelope protein is highly glycosylated to protect epitopes, then the protein stability is improved, but the breadth of neutralizing antibody response is limited
Solution Approach 1:
The patent modifies the glycosylation pattern and protein conformation through specific mutations, changing the accessibility parameters of epitopes. This allows maintenance of glycan shield for stability while exposing conserved neutralizing epitopes that can be recognized by broadly neutralizing antibodies across different HIV clades
Data Source
AI summary
Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.